JAPAN PRECISION MEDICINE FORUM

The Japan Precision Medicine Forum will convene leaders from the pharmaceutical and biotech industries, oncology experts, and diagnostic innovators to explore the next phase of precision medicine in Japan.

Join us to discover how integrated genomic data, advanced analytics, and strategic partnerships can drive faster, more equitable, and more effective cancer care, setting a new standard for precision oncology in Japan and beyond.

Advancing Precision Medicine in Japan

Discover how the collaboration between A.D.A.M. Innovations and SOPHiA GENETICS brings global best practices in precision oncology to Japan, combining advanced analytics through SOPHiA DDM™ with approaches such as MSK-ACCESS® and MSK-IMPACT®, developed and used in clinical routine by Memorial Sloan Kettering Cancer Center (MSK). This integrated approach advances liquid biopsy and solid tumor research and clinical applications in Japan, delivering high-quality, scalable, and clinically actionable insights. All testing and data processing are conducted within Japan, ensuring full compliance with local regulations and strict data sovereignty, while supporting the nationwide deployment of precision diagnostics through A.D.A.M. Innovations.

Expanding Access to High-Quality Genomic Testing in Japan

Explore how this partnership is accelerating access to robust, clinically validated genomic testing across Japan, enhancing local capabilities in oncology care and supporting broader access to precision medicine.

Accelerating Clinical Development Through Real-World Data Integration

Learn how integrating Japan-specific genomic and clinical datasets with the SOPHiA DDM™ platform enable advanced biomarker discovery, supports clinical trial optimization, and strengthens companion diagnostic (CDx) strategies tailored to the Japanese population.

Generating Evidence to Support Regulatory and Commercial Pathways in Japan

Understand how localized evidence generation can accelerate regulatory approval, inform reimbursement strategies, and expand the clinical utility of precision oncology solutions in Japan and broader Asia.　

Keynote speakers:

• Dr. Kojo S.J. Elenitoba-Johnson, Memorial Sloan Kettering Cancer Center

• Dr. Hiroshi Nishihara, Keio University

• Dr. Jurgi Camblong, Founder and CEO, SOPHiA Genetics

• Dr. Philippe Menu, Chief Medical and Product Officer, SOPHiA Genetics

• Michel Mommejat, President, A.D.A.M. Innovations